Neurocrine Biosciences (NBIX) Change in Cash (2010 - 2026)

Neurocrine Biosciences' Change in Cash history runs 17 years deep, the most recent figure standing at -$446.5 million for Q1 2026.

• Quarterly Change in Cash fell 1047.81% year-over-year to -$446.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.4 million (up 135.81% YoY) and the FY2025 annual result came in at $480.0 million, up 2751.93% from the prior year.
• Change in Cash was -$446.5 million for Q1 2026 at Neurocrine Biosciences, down from $372.8 million in the prior quarter.
• Across five years, Change in Cash topped out at $372.8 million in Q4 2025 and bottomed at -$446.5 million in Q1 2026.
• A 5-year average of -$4.1 million and a median of $48.9 million in 2022 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2025 — Change in Cash jumped 421.1% — and 2026, when it tumbled 1047.81%.
• Neurocrine Biosciences' Change in Cash stood at $50.7 million in 2022, then tumbled by 184.02% to -$42.6 million in 2023, then plunged by 172.54% to -$116.1 million in 2024, then soared by 421.1% to $372.8 million in 2025, then slumped by 219.77% to -$446.5 million in 2026.
• Business Quant data shows NBIX's Change in Cash at -$446.5 million in Q1 2026, $372.8 million in Q4 2025, and $76.2 million in Q3 2025.